[go: up one dir, main page]

ECSP003555A - Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion - Google Patents

Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion

Info

Publication number
ECSP003555A
ECSP003555A EC2000003555A ECSP003555A ECSP003555A EC SP003555 A ECSP003555 A EC SP003555A EC 2000003555 A EC2000003555 A EC 2000003555A EC SP003555 A ECSP003555 A EC SP003555A EC SP003555 A ECSP003555 A EC SP003555A
Authority
EC
Ecuador
Prior art keywords
salt
mammals
diphosphate
diffosphate
homoerithromycin
Prior art date
Application number
EC2000003555A
Other languages
English (en)
Inventor
Robert John Rafka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP003555A publication Critical patent/ECSP003555A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invención se refiere a una nueva sal dfosfato cristalina de (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[ [2,6-didesoxi-3-C-metil-4-C-[(propilamino)metil]&-Lribo'hexopiranosil]oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-11- [ [3,4,6-tridesoxi-3-(dimetilamino) - B-D-xilo-hexopiranosil]oxi]-1-oxa-6-azaciclopentadecan-15-ona que es útil como agente antibacteriano y antiprotozoario en mamíferos.Esta invención también se refiere a composiciones farmaceúticas que contienen la base libre de la sal difosfato y a los procedimientos de tratamiento de infecciones bacterianas y protozoarias en mamíferos, mediante la administración de la base libre de la sal difosfato a mamíferos que requieren dicho tratamiento. La base libre de sal difosfato de la presente invención posee una potente actividad contra diversas infecciones bacterianas y protozoarias cuando se administra por vía parenteral a mamíferos.
EC2000003555A 1999-06-30 2000-06-30 Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion ECSP003555A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14168199P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
ECSP003555A true ECSP003555A (es) 2002-01-25

Family

ID=22496734

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003555A ECSP003555A (es) 1999-06-30 2000-06-30 Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion

Country Status (42)

Country Link
US (3) US6465437B1 (es)
EP (1) EP1189913B1 (es)
JP (1) JP2003503506A (es)
KR (1) KR100442508B1 (es)
CN (2) CN101220067A (es)
AP (1) AP2001002370A0 (es)
AR (1) AR035551A1 (es)
AT (1) ATE286906T1 (es)
AU (1) AU772277B2 (es)
BG (1) BG65587B1 (es)
BR (1) BR0012091A (es)
CA (1) CA2376748C (es)
CO (1) CO5190679A1 (es)
CZ (1) CZ20014571A3 (es)
DE (1) DE60017399T2 (es)
EA (1) EA004235B1 (es)
EC (1) ECSP003555A (es)
EE (1) EE05068B1 (es)
ES (1) ES2233380T3 (es)
GT (2) GT200000105AA (es)
HN (1) HN2000000090A (es)
HR (1) HRP20010919B1 (es)
HU (1) HUP0201693A3 (es)
IL (1) IL146408A0 (es)
IS (1) IS6159A (es)
MA (1) MA26745A1 (es)
MX (1) MXPA02000058A (es)
MY (1) MY133360A (es)
NO (1) NO20016221D0 (es)
OA (1) OA11965A (es)
PA (1) PA8496901A1 (es)
PE (1) PE20010287A1 (es)
PL (1) PL201891B1 (es)
PT (1) PT1189913E (es)
SK (1) SK286243B6 (es)
TN (1) TNSN00143A1 (es)
TR (1) TR200103834T2 (es)
UA (1) UA71013C2 (es)
UY (1) UY26221A1 (es)
WO (1) WO2001002414A1 (es)
YU (1) YU88701A (es)
ZA (1) ZA200110453B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6791660B1 (en) * 2002-02-12 2004-09-14 Seiko Epson Corporation Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN110885351A (zh) * 2019-12-17 2020-03-17 海门慧聚药业有限公司 泰拉霉素磷酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての8a−アザライド
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
CA2372206C (en) * 1999-05-18 2006-01-10 Pfizer Products Inc. Novel crystalline forms of a macrolide antibiotic
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

Also Published As

Publication number Publication date
BG106123A (en) 2002-05-31
EP1189913B1 (en) 2005-01-12
SK18922001A3 (sk) 2002-04-04
PA8496901A1 (es) 2002-08-26
HUP0201693A2 (en) 2002-10-28
NO20016221L (no) 2001-12-19
US20030092642A1 (en) 2003-05-15
MA26745A1 (fr) 2004-12-20
EA200101178A1 (ru) 2002-06-27
DE60017399T2 (de) 2006-03-30
DE60017399D1 (de) 2005-02-17
ES2233380T3 (es) 2005-06-16
MXPA02000058A (es) 2002-07-02
MY133360A (en) 2007-11-30
PE20010287A1 (es) 2001-03-05
EA004235B1 (ru) 2004-02-26
GT200000105A (es) 2001-12-20
CA2376748C (en) 2006-03-14
EE05068B1 (et) 2008-08-15
HUP0201693A3 (en) 2003-03-28
CN101220067A (zh) 2008-07-16
IL146408A0 (en) 2002-07-25
OA11965A (en) 2006-04-12
UY26221A1 (es) 2001-01-31
TNSN00143A1 (fr) 2005-11-10
UA71013C2 (uk) 2004-11-15
HRP20010919B1 (en) 2005-06-30
ZA200110453B (en) 2003-03-04
AR035551A1 (es) 2004-06-16
PL201891B1 (pl) 2009-05-29
SK286243B6 (sk) 2008-06-06
KR20020016875A (ko) 2002-03-06
IS6159A (is) 2001-11-13
JP2003503506A (ja) 2003-01-28
CZ20014571A3 (cs) 2002-04-17
US20040209826A1 (en) 2004-10-21
KR100442508B1 (ko) 2004-07-30
US7297682B2 (en) 2007-11-20
AU4943900A (en) 2001-01-22
CO5190679A1 (es) 2002-08-29
TR200103834T2 (tr) 2002-05-21
BG65587B1 (bg) 2009-01-30
BR0012091A (pt) 2002-04-02
NO20016221D0 (no) 2001-12-19
PT1189913E (pt) 2005-04-29
YU88701A (sh) 2004-09-03
PL352900A1 (en) 2003-09-22
CA2376748A1 (en) 2001-01-11
HN2000000090A (es) 2001-04-20
ATE286906T1 (de) 2005-01-15
EE200100699A (et) 2003-02-17
AU772277B2 (en) 2004-04-22
US6861412B2 (en) 2005-03-01
US6465437B1 (en) 2002-10-15
AP2001002370A0 (en) 2001-12-31
CN1358188A (zh) 2002-07-10
GT200000105AA (es) 2001-12-20
EP1189913A1 (en) 2002-03-27
WO2001002414A1 (en) 2001-01-11
HRP20010919A2 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
BR9814601A (pt) "macrólidos"
BR0112863A (pt) Antibióticos macrólidos
BG101485A (en) Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides
HUP0104241A2 (hu) Azitromicin-etanolát, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmények
UA39131C2 (uk) Склад для обробки порожнини рота
PT952835E (pt) Metodo de tratamento de doenca cardiaca causada por chlamidia pneumoniae
BR9916969A (pt) Antibióticos cetólidos
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
ES8203962A1 (es) Un procedimiento para la preparacion de una macrolida
CA2132429A1 (en) Alkylthio alkyl avermectins are active antiparasitic agents
BR9306741A (pt) Derivados de macrólidos antibióticos com anel de 16 membros
ECSP003555A (es) Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
PT1133511E (pt) Novos intermediarios e processo para preparar um agente antibiotico macrolido a partir deles
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
IL126625A0 (en) 6-o-substituted erythromycin compounds and method for making same
RS82504A (en) Isostructural pseudopolymorphs of 9- deoxo-9a-aza-9a-methil- 9a- homoerythromycin a
BR0100228A (pt) Macrolìdeos com 13 e 14 elementos antibacterianos e procinéticos e seus intermediários
ES2161764T3 (es) Conjugados de antraciclina, su preparacion y su utilizacion como agente antitumorales.
EP0416327A3 (en) Chemical derivatives of antibiotics ll-e19020 alpha and beta